Technology Evaluation Center
Founded in 1985, the Technology Evaluation Center (TEC) is housed and supported by the Blue Cross and Blue Shield Associations, the membership organization for the Blue Cross and Blue Shield health insurance plans. TEC's purpose is to evaluate medical technologies and make recommendations regarding their use. TEC's reports, known as 'assessments', are publicly available.
With regard to genetic/genomic testing, the following assessments have been published by TEC:
- Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy (HCM): TEC does recommend genetic testing for individuals who are at-risk for the development of HCM, defined quite specifically those having a close relative with established HCM, AND, when there is a known pathogenic gene mutation present in an affected relative.